<b>Gapping up <br/>In reaction to strong earnings/guidance</b>: ACI +26.5%, PGN +12.5%, AVEO +12.2%, RXDX +8.5%, DF +7.8%, HZNP +6.1%, ICON +5.8%, SNI +4.2%, INO +4%, RLD +3.6%, NSAM +2.5%, CTCM +2.4%, ENDP +1.9%, EXXI +1%<br/><br/><b>M&A news:</b> PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business)<br/><b><br/>Select metals/mining stocks trading higher: </b>RGLD +1.4%, RIO +0.9%, SSRI +0.7%, AEM +0.7%, KGC +0.6%, GG +0.5%<br/><br/><b>Select oil/gas related names showing strength</b>: APA +12.9% (still checking), RIG +2.3% (still checking), SDRL +2.2% (still checking), OAS +2% (still checking), STO +1.8% (still checking), NBL +1% (still checking), RDS.A +0.8% (still checking)<br/><br/><b>Other news: </b>AVXL +20.7% (presents positive safety and cognitive efficacy data for ANAVEX 2-73; study met the primary objective of safety), PCL +14% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business), TKAI +13.4% (presents new data highlighting the anti-tumor activity of galeterone in multiple preclinical tumor models), IMNP +9.6% (announces FDA acceptance of its IND application for Bertilimumab, to treat Bullous Pemphigoid; enables expanded recruitment for its clinical trials), RXDX +8.5% (reports interim data from RXDX-105 Phase 1 clinical trial; RXDX-105 was well tolerated to date), WTW +6.3% (cont strength), RDHL +4.5% (RedHill Biopharma and IntelGenx Corp announce that they have been granted marketing approval in Germany, for Rizaport 5mg and 10mg to treat migraines), CRIS +4% (presents preclinical data from oral small molecule PD-L1/VISTA and IRAK4 programs), MT +2.8% (Telegraph discusses that Europe wants China to stop dumping steel output), ERIC +2.2% (Cisco Systems and Ericsson form strategic partnership), COLL +1.8% (announces FDA approval for its NDA for Xtampza ER), GALE +1.7% (reports data from its GALE-301 and GALE-302 clinical programs)<br/><br/><b>Analyst comments:</b> AEZS +24.6% (upgraded to Buy at Canaccord Genuity), PZZA +3.2% (upgraded to Overweight at KeyBanc)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance: </b>KNDI -12%, PLUG -8.3%, NVAX -6.8%, PCLN -5.9%, EVEP -4.8%, AOI -3%, ANTH -3%, BITA -2.8%, MNKD -2.4%, FXEN -0.9%<br/><br/><b>M&A news: </b>WY -3.7% (Weyerhaeuser and Plum Creek (PCL) to merge; all-stock transaction followed by $2.5 bln post-closing share repurchase; WY to review strategic alternatives for its Cellulose Fibers business)<br/><br/><b>Select large pharma names showing weakness:</b> SNY -2.1%, AZN -1.7%, SHPG -1.6%, NVS -1%, GSK -0.5%<br/><br/><b>Other news:</b> XOMA -8.9% (cont weakness), NBG -5.3% (still checking), AGIO -5.1% (reports data from dose-escalation Phase 1 study of AG-120), ITUB -2.5% (still checking), CALA -2.4% (reports new Phase 1 solid tumor dose expansion data of CB-839), BHP -1.3% (updates on the incident at its Samarco mine, places FY16 production guidance under review)<br/><br/><b>Analyst comments:</b> GLUU -4.3% (downgraded to Hold at The Benchmark Company), CENX -2.2% (downgraded to Neutral from Buy at Nomura), SNY -2.1% (downgraded to Mkt Perform from Outperform at Bernstein), OVAS -1.9% (downgraded to Mkt Perform from Outperform at Leerink Partners), ADSK -1.5% (downgraded to Neutral from Buy at UBS ), SSYS -1.3% (downgraded to Hold from Buy at Deutsche Bank), CTIC -0.8% (downgraded to Hold at WallachBeth), AA -0.7% (downgraded to Neutral from Buy at Nomura), QCOM -0.6% (downgraded to Neutral from Buy at Nomura).<br/><br/>Briefing.com